The Delivery Problem: Getting CRISPR Into the Right Cell

The hardest part of CRISPR therapy isn't the editing. It's the delivery.

You have the guide RNA, you have Cas9, you have a clear target. Now you need to get these molecular tools into the nucleus of the specific cell type you want to edit — without killing the cell, without triggering an immune response, and without accidentally editing something else.

There are currently four main approaches, each with tradeoffs.

**Viral vectors** — most commonly adeno-associated viruses (AAVs) — are the most clinically advanced. AAVs are naturally good at entering cells and depositing their genetic payload. Researchers swap out the viral genes and replace them with Cas9 instructions. Different AAV serotypes (subtypes) have preferences for different tissues: AAV9 reaches the central nervous system efficiently; AAV8 favors the liver. The problem: AAVs have a packaging size limit of around 4.7 kilobases. Cas9 from *S. pyogenes* is about 4.2 kb just as a gene — leaving almost no room for the guide RNA and other regulatory elements. Smaller Cas9 variants (like SaCas9 from *Staphylococcus aureus*) help, but it's tight.

**Lipid nanoparticles (LNPs)** are the delivery system used for Casgevy, the first FDA-approved CRISPR therapy. LNPs are essentially tiny fat bubbles that encapsulate the CRISPR components — typically as mRNA for Cas9 and a synthetic guide RNA — and fuse with cell membranes to release their cargo inside. The liver absorbs LNPs very efficiently. The limitation: LNPs mostly stay in the liver. Targeting other tissues requires modifying the nanoparticle surface, an active area of research.

**Electroporation** works *ex vivo* — cells are taken out of the patient's body, zapped with an electric field that temporarily opens pores in the cell membrane, flooded with CRISPR components, and then returned to the patient. Casgevy uses this approach for editing blood stem cells. It's reliable and bypasses the immune-response problem, but it only works for cells you can extract, edit, and reinfuse (blood cells, some immune cells).

**Base editors and prime editors** are newer variants that don't require a double-strand break at all. They chemically convert one base to another (A→G, C→T) or use a reverse-transcriptase mechanism to write new sequences into the genome. These reduce the off-target risk profile significantly but can only make specific types of changes.

The practical implication: where CRISPR can currently be used therapeutically is largely determined by which delivery method works for that tissue. Blood diseases are tractable today. The brain, the muscle, the lungs — much harder.

The Delivery Problem: Getting CRISPR Into the Right Cell

// COMMENTS

ON THIS PAGE